Literature DB >> 21126732

The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.

Michael Kometer1, B Rael Cahn, David Andel, Olivia L Carter, Franz X Vollenweider.   

Abstract

BACKGROUND: Recent findings suggest that the serotonergic system and particularly the 5-HT2A/1A receptors are implicated in visual processing and possibly the pathophysiology of visual disturbances including hallucinations in schizophrenia and Parkinson's disease.
METHODS: To investigate the role of 5-HT2A/1A receptors in visual processing the effect of the hallucinogenic 5-HT2A/1A agonist psilocybin (125 and 250 μg/kg vs. placebo) on the spatiotemporal dynamics of modal object completion was assessed in normal volunteers (n = 17) using visual evoked potential recordings in conjunction with topographic-mapping and source analysis. These effects were then considered in relation to the subjective intensity of psilocybin-induced visual hallucinations quantified by psychometric measurement.
RESULTS: Psilocybin dose-dependently decreased the N170 and, in contrast, slightly enhanced the P1 component selectively over occipital electrode sites. The decrease of the N170 was most apparent during the processing of incomplete object figures. Moreover, during the time period of the N170, the overall reduction of the activation in the right extrastriate and posterior parietal areas correlated positively with the intensity of visual hallucinations.
CONCLUSIONS: These results suggest a central role of the 5-HT2A/1A-receptors in the modulation of visual processing. Specifically, a reduced N170 component was identified as potentially reflecting a key process of 5-HT2A/1A receptor-mediated visual hallucinations and aberrant modal object completion potential.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21126732     DOI: 10.1016/j.biopsych.2010.10.002

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  20 in total

1.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

3.  Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Authors:  José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2013-06-21       Impact factor: 4.530

4.  A bidirectional link between brain oscillations and geometric patterns.

Authors:  Federica Mauro; Antonino Raffone; Rufin VanRullen
Journal:  J Neurosci       Date:  2015-05-20       Impact factor: 6.167

5.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.

Authors:  Frederick S Barrett; Theresa M Carbonaro; Ethan Hurwitz; Matthew W Johnson; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2018-07-30       Impact factor: 4.530

6.  Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.

Authors:  André Schmidt; Rosilla Bachmann; Michael Kometer; Philipp A Csomor; Klaas E Stephan; Erich Seifritz; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

7.  Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience.

Authors:  Vojtěch Viktorin; Inga Griškova-Bulanova; Aleksandras Voicikas; Dominika Dojčánová; Peter Zach; Anna Bravermanová; Veronika Andrashko; Filip Tylš; Jakub Korčák; Michaela Viktorinová; Vlastimil Koudelka; Kateřina Hájková; Martin Kuchař; Jiří Horáček; Martin Brunovský; Tomáš Páleníček
Journal:  J Pers Med       Date:  2022-06-19

Review 8.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

Review 9.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  Serotonergic psychedelics temporarily modify information transfer in humans.

Authors:  Joan Francesc Alonso; Sergio Romero; Miquel Àngel Mañanas; Jordi Riba
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-28       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.